Refractory IGκ/IRF4-positive DLBCL with CDKN2A/2B deletion

Ann Hematol. 2014 May;93(5):893-4. doi: 10.1007/s00277-013-1889-8. Epub 2013 Aug 29.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Antineoplastic Agents / therapeutic use
  • Cyclin-Dependent Kinase Inhibitor p15 / deficiency
  • Cyclin-Dependent Kinase Inhibitor p15 / genetics*
  • Cyclin-Dependent Kinase Inhibitor p16 / deficiency
  • Cyclin-Dependent Kinase Inhibitor p16 / genetics*
  • Drug Resistance, Neoplasm*
  • Fatal Outcome
  • Gene Deletion
  • Gene Expression
  • Humans
  • Immunoglobulins / genetics*
  • Interferon Regulatory Factors / genetics*
  • Lymphoma, Large B-Cell, Diffuse / drug therapy
  • Lymphoma, Large B-Cell, Diffuse / genetics*
  • Lymphoma, Large B-Cell, Diffuse / pathology
  • Male
  • Middle Aged

Substances

  • Antineoplastic Agents
  • CDKN2B protein, human
  • Cyclin-Dependent Kinase Inhibitor p15
  • Cyclin-Dependent Kinase Inhibitor p16
  • IgK
  • Immunoglobulins
  • Interferon Regulatory Factors
  • interferon regulatory factor-4